Is Novo Nordisk's Brutal Sell-Off Really a Buying Opportunity?
Novo Nordisk (NVO) once dominated the weight-loss revolution with Wegovy and Ozempic, but Eli Lilly (LLY) has seized the lead with Zepbound and its pipeline momentum. The Danish…
Written byRich DupreySource: Money Morning – We Make Investing Profitable
Novo Nordisk (NVO) once dominated the weight-loss revolution with Wegovy and Ozempic, but Eli Lilly (LLY) has seized the lead with Zepbound and its pipeline momentum. The Danish giant’s latest bid to regain momentum – CagriSema – came up short in a high-stakes head-to-head trial, triggering a brutal 16% stock plunge to levels not seen […]
The post Is Novo Nordisk's Brutal Sell-Of